Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Abstract Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping‐mutated NSCLC. However, its feasibility for perioperative...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Rongzhen Li, Xiaoyan Liu, Yan Xu, Jing Zhao, Wei Zhong, Xiaoxing Gao, Minjiang Chen, Mengzhao Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2024-11-01
Edice:	Thoracic Cancer
Témata:	MET exon 14 skipping mutation neoadjuvant non‐small cell lung cancer tepotinib
On-line přístup:	https://doi.org/10.1111/1759-7714.15459
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!